GlassScriptPhysician profile
Rebeca Rivera
NPI 1184113094
$3,649.07
in general payments reported to CMS, 2019-2025
28 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $112 · 2023: $693 · 2024: $738 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $656.18 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $469.37 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $380.27 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $323.67 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.82 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $202.07 | 2025 | Auvelity |
| Exact Sciences Corporation | $187.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $143.77 | 2022-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $140.23 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $134.42 | 2023-2025 | Freestyle Libre |
| Intuitive Surgical, INC. | $103.24 | 2025 | |
| Amgen INC. | $86.69 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Paratek Pharmaceuticals, INC. | $69.05 | 2024 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $65.90 | 2025 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $63.71 | 2022-2023 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.37 | 2023 | |
| Sanofi-Aventis U.S. LLC | $43.71 | 2023-2024 | |
| Mvp Orthopedics INC | $43.43 | 2023 | |
| Pfizer INC. | $37.72 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $35.04 | 2022 | |
| Glaxosmithkline, LLC. | $34.86 | 2023 | Shingrix |
| Cequr Corporation | $32.31 | 2023 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $27.86 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.46 | 2025 | Jardiance |
| Lundbeck LLC | $22.22 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.79 | 2022 | |
| Merck Sharp & Dohme LLC | $19.02 | 2023 | Verquvo, Steglatro |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeca Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.